Search 

New technologies have the potential to transform healthcare and medical research by increasing efficiency and creating more personalised medicine.



Ctrl Group is a team of designers, researchers, software developers and healthcare experts who work internationally with healthcare companies and providers who want to use new technology to improve people’s health. We create products and services that are effective, engaging and safe.

Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based platform, delivers actionable insights into therapies to our pharmaceutical and biotech partners. Oncimmune’s ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune's immuno diagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally. Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a partner representative office in Shanghai, China.

Pangaea Data Limited have pioneered a product based on their novel unsupervised AI to unlock hidden value from unstructured textual health data, which comprises 80% of patient records and >90% of medical blogs and social media feeds. Pangaea’s product is used by scientists from the Biopharmaceutical industry to extract intelligence such as phenotypes (clinical features) so they can stratify patients effectively and find more patients for drug discovery, clinical trial and new product launches at scale, which is otherwise challenging, especially in the context of hard to diagnose conditions such as rare and chronic diseases where 60% of the patient population is not diagnosed properly. The company has access to more than 500 million patient electronic health records through its partnerships with hospitals and other such providers from the US, UK, Europe, South America and Asia Pacific.

Biopharmaceutical companies are also using the product to automatically generate clinical study reports and the likes from experimental data and to find adverse events for Pharmacovigilance purposes. Pangaea continually publish their work in high impact peer reviewed journals.

Pangaea is based in San Francisco, London and Hong Kong and was founded by experienced entrepreneurs who have raised more than £130 million through their academic research and is advised by leading experts from industry, Imperial College London and Stanford University.